Quest Diagnostics’ sponsored feature in PharmaVoice argues that pharmaceutical companies, spending more than $300 billion a year on R&D while seeing only about 12% of candidates win FDA approval, are leaning hard into predictive analytics to steady their commercialization odds. Parag More, executive director of life sciences data and analytics solutions at Quest, says models built from lab results and claims data estimate market size, flag undiagnosed patients, and prioritize physician outreach. Diagnostic data has effectively become strategic infrastructure, delivering near real-time views of disease prevalence and provider behavior that shorten the path from approval to adoption and sharpen launch execution.
Commercialization policy now pivots from messaging toward modeling. FDA approval marks only the midpoint in a product’s life; the real friction lies in finding eligible patients across fragmented systems. That is as much a data-governance test as it is a marketing puzzle. Predictive analytics using real-world lab data already expose underdiagnosis patterns that could reshape how companies budget for promotion, how payers evaluate diagnostic coverage, and how regulators read post-market evidence. The open question is compliance: how far expanded use of de-identified lab data for commercial purposes can go while still aligning with privacy and consent expectations. The outcome will likely steer upcoming guidance from FDA and HHS.
If lab-based predictive tools become standard fare in launch playbooks, diagnostics networks like Quest won’t just support commercialization, they’ll anchor it. Testing, market access, and provider education could merge into one continuous feedback channel, influencing everything from payer utilization management to formulary timing. Drug makers are already directing less spend toward mass-field promotion and more toward pinpointed physician education in precision and rare diseases. Whether CMS or privacy regulators move to define stricter limits on using predictive models in commercial strategy is still unclear. My bet? Watch the next two years closely; the regulatory swing could rewrite how launches are planned altogether.
